<DOC>
	<DOC>NCT00813813</DOC>
	<brief_summary>Study to show the effectiveness and safety of a single injection of rhGDF5 into a degenerating single spinal disc in treating lumbar level degenerative disc disease</brief_summary>
	<brief_title>Intradiscal rhGDF-5 Phase I/II Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>1. Persistent low back pain, with at least 3 months of nonsurgical therapy, at one symptomatic lumbar level (L3/L4 to L5/S1) as confirmed using a standardized discography protocol 2. Oswestry Disability Index of 30 or greater 3. Low back pain score greater than or equal to 4 cm as measured by VAS, at Visit 1 baseline and on day of treatment to confirm eligibility prior to administration 1. Persons unable to have a discogram, CT or an MRI 2. Abnormal neurological exam at baseline (e.g., radiculopathy) 3. Radicular pain 4. Leak of contrast agent during the discogram, into the epidural space (does not include leak of contrast agent along the needle track) 5. MRI findings demonstrate any of the following:路 Suspected disc appears normal路 &gt;50% decrease in disc height路 Modic changes, and/or路 Presence of osteophytes or significant facet arthrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>